BiomX Inc. (PHGE)

NYSEAMERICAN: PHGE · IEX Real-Time Price · USD
0.450
+0.094 (26.40%)
Mar 28, 2024, 3:59 PM EDT - Market closed

Company Description

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria.

It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).

It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials.

The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S.

aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment.

BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

BiomX Inc.
BiomX logo
Country Israel
Founded 2015
Industry Biotechnology
Sector Healthcare
Employees 54
CEO Jonathan Eitan Solomon MBA

Contact Details

Address:
22 Einstein St., 4th Floor
Ness Ziona, L3 7414003
Israel
Phone (972) 72 394 2377
Website biomx.com

Stock Details

Ticker Symbol PHGE
Exchange NYSEAMERICAN
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001739174
CUSIP Number 09090D103
ISIN Number US09090D1037
SIC Code 2836

Key Executives

Name Position
Jonathan Eitan Solomon MBA Chief Executive Officer and Director
Marina Wolfson CPA Chief Financial Officer and Secretary
Dr. Merav Bassan Ph.D. Chief Development Officer
Prof. Rotem Sorek Ph.D. Scientific Founder
Dr. Eran Elinav M.D., Ph.D. Scientific Founder
Dr. Timothy K. Lu M.D., Ph.D. Scientific Founder
Inbal Benjamini-Elran C.H.R.O
Assaf Oron Chief Business Officer

Latest SEC Filings

Date Type Title
Mar 26, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Mar 25, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Mar 22, 2024 SC 13D General statement of acquisition of beneficial ownership
Mar 21, 2024 8-K/A [Amend] Current report
Mar 19, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Mar 18, 2024 8-K Current Report
Mar 8, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Mar 6, 2024 8-K Current Report
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 2, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals